The American Civil Liberties Union and Myriad Genetics are heading to court for another bout over the patentability of DNA isolated from BRCA cancer genes. The Biotechnology Industry Organization urges the Federal Circuit to protect composition of matter patent claims and Lilly calls for the court to create a bright patent-eligibility line.
Searching more than a year for a development partner for its Phase II-ready hepatocellular carcinoma candidate, RNAi pioneer Alnylam found one in U.S./China hybrid Ascletis. In lieu of an upfront payment, Alnylam instead will receive rights to Ascletis’ trial data for use in other registrational programs for the candidate, ALN-VSP.
An FDA advisory committee will dive into tablet-scoring issues at a meeting in August.
Financings of the fortnight finds that publicly held biopharma companies raised over $3 billion in secondary offerings through the first six months of 2012. Plus news on recent financial activity by GenKyoTex, Synageva, Nektar Therapeutics and Edmond de Rothschild Investment Partners.
FDA is soliciting a single source application for an award to develop a patient-based registry to evaluate the association of exposure to gadolinium based contrast agents and nephrogenic systemic fibrosis.